New CT scanner could sharpen heart disease diagnosis
NCT ID NCT05240807
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new type of CT scanner (photon-counting detector CT) to see if it gives clearer images of heart arteries and blood flow compared to standard CT and nuclear stress tests. Researchers enrolled 276 adults with suspected coronary artery disease. The goal was to see if the new scanner provides more accurate information about blockages and perfusion defects, which could help doctors make better treatment decisions.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Photon-counting detector CT (PCD-CT) scanner
- What this could lead to
- If successful, this new CT technology could provide clearer, more detailed images of heart arteries, helping doctors make more accurate diagnoses and better treatment plans for patients with suspected coronary artery disease.
- What could go wrong
- This is a completed early-stage study with 276 participants, so results may not apply to all patients. The new scanner's benefits over existing methods are still being evaluated, and it may not lead to changes in patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
276 people
The number who actually took part.
- Started
-
Aug 2022
- Finished
-
Mar 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 99 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients referred for coronary artery cardiac CT imaging or nuclear medicine or MRI cardiac perfusion within the Department of Radiology or Cardiology. * Patients who are able and willing to sign the informed consent will be enrolled * Negative pregnancy test if subject is of child-bearing age (females of child-bearing potential will be screened for pregnancy using a urine pregnancy test, which will be administered by the unit study coordinator at no cost to the patient). Exclusion Criteria: * Patients unable to provide written informed consent * Pregnancy * eGFR ≤ 30 * History of prior moderate or severe contrast reaction includes: unresponsiveness, severe respiratory distress, convulsions, arrhythmia, cardiopulmonary distress, progressive angioedema, laryngeal edema, dyspnea, bronchospasm, symptomatic tachycardia, symptomatic bradycardia, hypotension, hypertensive crisis. * Any history of required premedication prior to iodinated contrast administration. * Patients that consent to participation but do not undergo their clinically-indicated, contrast-enhanced CT, or nuclear medicine or MR perfusion scanning for any reason (e.g., bad IV, infiltration, reaction, change in indication). * Patients experiencing atrial fibrillation, premature ventricular contractions or other heart rhythm abnormalities * Hospitalized patients or patients under care in the Emergency Department Specific exclusion criteria only for participation in the cardiac stress test arm of this study (requiring administration of Regadenoson): * Anything by mouth within three hours of the examination * Known hypersensitivity to Regadenoson, Adenosine, or Dipyridamole. * Active ongoing wheezing or poorly controlled asthma or COPD (hospitalized within last month or receiving treatment for flair within last month). * Second (type I or II) or third degree atrioventricular (AV) block or sinus node dysfunction unless patient has functioning artificial pacemaker. * Ingested greater than 4 oz. of caffeine within the last 12 hours. * Currently experiencing unstable coronary syndrome. * Uncontrollable seizures within the last 3 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Coronary artery disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart bypass surgeons test which vein layout keeps grafts open
- A soft patch that watches your heart beat in real time
- Zapping the ear: a new way to stop Post-Surgery heart rhythm problems?
- Squeeze a ball, lower your blood pressure? heart trial puts handgrip exercise to the test
- New heart scan aims to spot hidden plaque before it strikes
- Can a kidney ultrasound scan warn of kidney damage after heart bypass surgery?